Home > Insider Trading > Merck Sharp & Dohme Corp. > Profile

Merck Sharp & Dohme Corp. (MRK)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Pharmaceutical Preparations

Insider Roster

E Carlos Represas, Director, 2011-01-20
T Richard Clark, Officer, Director, 2009-11-04
S Peter Kim, Officer, 2009-11-04

E Carlos Represas, Director, 2011-01-20
T Richard Clark, Officer, Director, 2009-11-04
S Peter Kim, Officer, 2009-11-04
A Celia Colbert, Officer, 2009-11-04
John Canan, Officer, 2009-11-04
C Kenneth Frazier, Officer, 2009-11-04
N Bruce Kuhlik, Officer, 2009-11-04
Stefan Oschmann, Officer, 2009-11-04
A Willie Deese, Officer, 2009-11-04
M Mirian Weir Graddick, Officer, 2009-11-04
Chris J Scalet, Officer, 2009-11-04
E Mark Mcdonough, Officer, 2009-11-04
H Adam Schechter, Officer, 2009-11-04
P Wendell Weeks, Director, 2009-11-04
C Peter Wendell, Director, 2009-11-04
Md O Samuel Thier, Director, 2009-11-04
M Anne Tatlock, Director, 2009-11-04
E Thomas Shenk, Director, 2009-11-04
B Rochelle Lazarus, Director, 2009-11-04
N Willam Kelley, Director, 2009-11-04
R Harry Jacobson, Director, 2009-11-04
Jr B William Harrison, Director, 2009-11-04
F Steven Goldstone, Director, 2009-11-04
H Thomas Glocer, Director, 2009-11-04
R Thomas Cech, Director, 2009-11-04
A Leslie Brun, Director, 2009-11-04
G Margaret Mcglynn, Officer, 2009-04-27

Show All Insiders (27)

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Kelley Director	$33.22	550	$18,268.75	750	2006-01-18	Filing
Kelley Director	$45.65	200	$9,130.56	200	2002-09-24	Filing

News See All

Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating

Merck & Co., Inc. (NYSE:MRK) is one of the top cheap pharmaceutical stocks to buy now. Goldman Sachs analyst Asad Haider maintained a bullish stance on Merck & Co., Inc.

Keep Reading →

August 4th, 2025 - News

11 Cheap Pharmaceutical Stocks to Buy Now

The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...

Keep Reading →

August 3rd, 2025 - Hedge Funds News

Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer

Merck & Co., Inc.

Keep Reading →

August 1st, 2025 - News

13 Stocks That Jim Cramer Recently Talked About

In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the recent activity in the liquefied natural gas (LNG) industry after Europe pledged to buy billions of dollars of US energy...

Keep Reading →

July 31st, 2025 - News

Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM

Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds.

Keep Reading →

July 30th, 2025 - News

Jim Cramer Recently Talked About These 19 Stocks

“Let me start with the negatives because they are visible. They matter, and they cut President Trump's way. Today, three very big household name companies reported jarring quarters.

Keep Reading →

July 30th, 2025 - Hedge Funds News

Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript

Operator: Thank you for standing by. Welcome to the Merck & Co., Inc., Rahway, N.J., USA Q2 Sales and Earnings Conference Call. [Operator Instructions] This call is being recorded.

Keep Reading →

July 30th, 2025 - News Transcripts

10 Most Undervalued Blue Chip Stocks to Buy According to Hedge Funds

On July 24, Emily Roland, Manulife John Hancock Investments co-chief investment strategist, appeared on CNBC’s 'Power Lunch' to talk about why it is now time to make profits from equity investments, ...

Keep Reading →

July 30th, 2025 - Hedge Funds News

Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Co., Inc.

Keep Reading →

July 28th, 2025 - News